Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Suspended 1Not yet recruiting 1No longer available 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

Specimen Handling 34Magnetic Resonance Spectroscopy 22Biopsy 20Cyclophosphamide 11venetoclax 7Nivolumab 6Azacitidine 6pembrolizumab 5Etoposide 5Cisplatin 5Bevacizumab 5fludarabine phosphate 4fludarabine 4Vincristine 4Taxes 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Radiosurgery 4Radiation 4Doxorubicin 4Cetuximab 4durvalumab 3decitabine and cedazuridine drug combination 3X-Rays 3Tacrolimus 3Surveys and Questionnaires 3Prednisone 3Platinum 3Leucovorin 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × taletrectinib × 1 year × Clear all
NCT06214793 2026-06-05

Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)

Case Comprehensive Cancer Center

Phase 2 Suspended
61 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡